New initiative aims to shorten timelines from early-stage research to late-stage clinical trials through regulatory reforms.

Federal health officials aim to speed up drug development and better compete with China.

New initiative aims to shorten timelines from early-stage research to late-stage clinical trials through regulatory reforms.